Document:

Careview Communications, Inc. 8-K

 

 

Exhibit 10.08

 

Execution
Copy

 

SEVENTH
AMENDMENT TO

NOTE AND WARRANT PURCHASE AGREEMENT

 

This
SEVENTH AMENDMENT TO NOTE AND WARRANT PURCHASE AGREEMENT, dated as of June 26, 2015 (this “Amendment”),
is made by and among CAREVIEW COMMUNICATIONS, INC., a Nevada corporation (the “Company”), and the undersigned
Majority Investors (as defined below).

 

WITNESSETH:

 

WHEREAS,
the Company, HealthCor Partners Fund, L.P. (“HealthCor Partners”), HealthCor Hybrid Offshore Master Fund, L.P.
(“HealthCor Hybrid” and, together with HealthCor Partners, the “HealthCor Parties”), and
certain additional investors (collectively with the HealthCor Parties, the “Investors”) are party to that certain
Note and Warrant Purchase Agreement, dated as of April 21, 2011 (as amended from time to time, including without limitation pursuant
to that certain Note and Warrant Amendment Agreement dated December 30, 2011, that certain Second Amendment to Note and Warrant
Purchase Agreement dated January 31, 2012, that certain Third Amendment to Note and Warrant Purchase Agreement dated August 20,
2013, that certain Fourth Amendment to Note and Warrant Purchase Agreement dated January 16, 2014, that certain Fifth Amendment
to Note and Warrant Purchase Agreement dated December 15, 2014, and that certain Sixth Amendment to Note and Warrant Purchase
Agreement dated March 31, 2015, the “Purchase Agreement”); and

 

WHEREAS,
the HealthCor Parties are the record and beneficial owners of Notes and Warrants representing a majority of the shares of Common
Stock issued or issuable (on an as converted basis) upon conversion of all Notes and Warrants held by any Investor (in such capacity,
the “Majority Investors”), and Section 7.9 of the Purchase Agreement provides that amendments to the Purchase
Agreement may be made pursuant to a written instrument executed by the Company and the Majority Investors;

 

WHEREAS,
the Company intends to enter into (i) that certain Credit Agreement, dated on or about the date hereof, among the Company, CareView
Communications, Inc., a Texas corporation and a wholly-owned subsidiary of the Company, as the borrower (“CareView TX”),
PDL BioPharma, Inc., a Delaware corporation, as the lender (“PDL”), and PDL, not individually, but as the agent
(the “PDL Credit Agreement”) and (ii) that certain Guarantee and Collateral Agreement dated on or about the
date hereof by and among the Company, CareView TX and certain subsidiary guarantors party thereto, as grantors, in favor of PDL,
as collateral agent (the “PDL Collateral Agreement”);

 

WHEREAS,
in connection with the PDL Credit Agreement, the Company intends to issue to PDL a warrant to purchase up to 4,444,445 shares
of Common Stock, as adjusted from time to time pursuant to the terms of such warrant, at an exercise price of $0.45 per share
(as may be amended, restated, supplemented or otherwise modified from time to time, the “PDL Warrant”);

 

    	 

    	 

    

 

WHEREAS,
pursuant to Section 7.9 of the Purchase Agreement and subject to the terms and conditions contained herein, the parties hereto
desire to amend the Purchase Agreement as set forth herein for the purposes of, among other things, permitting the Company and
its subsidiaries to enter into the PDL Credit Agreement, the PDL Collateral Agreement and the transactions contemplated thereby.

 

NOW,
THEREFORE, in consideration of the mutual promises, representations, warranties and covenants contained herein and in the
Purchase Agreement, which represent integral components of the transactions contemplated hereby and thereby and shall be fully
enforceable by the parties hereto, and for other good and valuable consideration, the receipt and sufficiency of which are hereby
acknowledged, the Company and the Investors mutually agree as follows:

 

1.            Definitions.
Capitalized terms used in this Amendment but not defined in this Amendment shall have the meanings ascribed to them in the Purchase
Agreement.

 

2.            Amendments
to Purchase Agreement.

 

a.              Section
6.4 (Investments) of the Purchase Agreement is hereby amended and restated in its entirety as follows:

 

6.4           Investments
and Acquisitions. Other than Permitted Investments, the Company shall not invest in, acquire any interest in (including the
acquisition of assets out of the ordinary course of business), or otherwise divert any of the funds of the Company to, any Person,
provided that the Company may make investments permitted by Sections 7.10(e), (f), (g), (h),
(i) or (j) of the PDL Credit Agreement.

 

b.              Section
6.8 (Guarantees and Loans) of the Purchase Agreement is hereby amended and restated in its entirety as follows:

 

6.8          Guarantees
and Loans. The Company shall not guarantee or endorse any obligation of, or make any advance or loan to, any Person, or assume
any contingent liability of any Person; provided that the Company may guarantee the obligations of any of its Subsidiaries
arising under the PDL Credit Agreement as contemplated by the PDL Collateral Agreement.

 

c.              Section
6.9 (Related Party Transactions) of the Purchase Agreement is hereby amended and restated in its entirety as follows:

 

6.9           Related
Party Transactions. The Company shall not enter into, or commit directly or indirectly to, any transaction, agreement or arrangement
with any Affiliate of the Company or with any manager, member, shareholder, officer, director or employee of the Company or any
Affiliate of the Company unless such transaction, agreement or arrangement is consummated on arms-length terms and is approved
by the Company’s Board of Directors; provided that the Company may enter into, without the foregoing limitations,
any transactions, agreements or arrangements with any Affiliate of the Company or with any manager, member, shareholder, officer,
director or employee of the Company or any Affiliate of the Company that are otherwise permitted by (i) Section 6.4 or
Section 6.10 of this Agreement or (ii) Section 7.7(c) of the PDL Credit Agreement.

 

    	- 2
                                                                                                                                                                             -

    	 

    

 

d.              Section
6.10 (Distributions; Redemptions) of the Purchase Agreement is hereby amended and restated in its entirety as follows:

 

6.10          Distributions;
Redemptions. The Company shall not directly or indirectly (a) declare or pay any dividend or distribution to any equityholder
of the Company, provided that the Company may declare or pay any dividend or distribution permitted under Sections 7.3(c)
or (d) of the PDL Credit Agreement; or (b) redeem, purchase, retire or otherwise extinguish any shares of the Company’s
capital stock or securities convertible into shares of the Company’s capital stock (except as required by any of the Transaction
Documents), provided that the Company may repurchase outstanding shares of its capital stock pursuant to a stock repurchase
program approved by the Board of Directors, including the Investor Designee, and provided, further, each such repurchase
is in compliance with the Company’s covenants under the PDL Credit Agreement and any other Indebtedness.

 

e.              The
first paragraph of Section 6.12 (Equity Issuance) of the Purchase Agreement is hereby amended by inserting,
immediately prior to the period (.) therein, a semi-colon (;) followed by the following proviso:

 

and
provided, further that the Company shall be permitted to issue, without requiring any such consent, (i) the PDL Warrant
and (ii) the shares of Common Stock issuable upon exercise of the PDL Warrant

 

f.               Section
6.13 (Sale of Assets) of the Purchase Agreement is hereby amended and restated in its entirety as follows:

 

6.13         Sale
of Assets. The Company shall not sell, lease or otherwise transfer any assets used or held for use in the Company’s
business outside of the ordinary course of business, provided that the Company may effect any sale, lease or other transfer
of assets permitted under Section 7.4 of the PDL Credit Agreement.

 

g.              Clause
(b) of the definition of “Permitted Encumbrances” in Section 7.1(j) of the Purchase Agreement is hereby
replaced in its entirety with the following:

 

(j)            “Permitted
Encumbrances” means (a) Liens in favor of and for the benefit of the Investors; (b) Liens in favor of and for the benefit
of PDL BioPharma, Inc., as agent under the PDL Collateral Agreement; (c) Liens permitted under Sections 7.2(d), (g),
(i), (k), (l), (m) or (n) of the PDL Credit Agreement; (d) non-exclusive licenses of the Company’s
or its Subsidiaries’ intellectual property granted to hospitals in the ordinary course of the Company’s or its Subsidiaries’
business pursuant to the Company’s or its Subsidiaries’ hospital contracts; (e) non-exclusive licenses of the Company’s
or its Subsidiaries’ intellectual property granted to Subsidiaries of the Company in connection with existing joint venture transactions
and future joint venture transactions entered into by the Company or its Subsidiaries to the extent involving new hospitals, new
businesses or international markets; (f) Liens in favor and for the benefit of joint venture partners arising from joint venture
transactions entered into by the Company or its Subsidiaries to the extent involving new hospitals, new businesses or international
markets; (g) Liens for Charges not delinquent or being contested in good faith and by appropriate proceedings and with respect
to which proper reserves have been established by the Company on its financial statements in accordance with GAAP; (h) deposits
or pledges to secure obligations under workers’ compensation, social security or similar laws, or with respect to unemployment
insurance; (i) bonded and statutory Liens of landlords, mechanics, workers, materialmens or other like Liens arising in the
ordinary course of the business with respect to obligations which are not delinquent; (j) Liens placed upon tangible assets
hereafter acquired to secure payment of the purchase price thereof, provided that any such Lien shall not encumber any
other property of the Company or its Subsidiaries; and (k) zoning restrictions and easements, licenses, covenants and other
restrictions that do not individually, or in the aggregate, materially and adversely affect the use of the Company’s or
its Subsidiaries’ owned, leased or licensed real property for its intended purpose in connection with the business.

 

    	- 3
                                                                                                                                                                             -

    	 

    

 

h.              The
definition of “Permitted Indebtedness” in Section 7.1(k) of the Purchase Agreement is hereby replaced in its
entirety with the following:

 

(k)           “Permitted
Indebtedness” shall mean (i) the indebtedness arising under the PDL Credit Agreement, in an amount not to exceed the
“First Lien Cap Amount” as such term is defined in the PDL Subordination Agreement, (ii) any indebtedness permitted
under Sections 7.1(d), (e), (g), (h), (j) or (k) of the PDL Credit Agreement and (iii)
purchase money indebtedness (including, but not limited to, mortgages, credit card indebtedness and automobile loans) of the Company
or its Subsidiaries or Capital Lease Obligations not to exceed the amount of $2,000,000.00 in the aggregate.

 

i.               Section
7.1 (Definitions) is hereby amended to add the following paragraphs thereto:

 

(o)           “PDL”
means PDL BioPharma, Inc., a Delaware corporation, together with its permitted successors and assignees.

 

(p)           “PDL
Collateral Agreement” means that certain Guarantee and Collateral Agreement dated on or about June 26, 2015 by and among
the Company, CareView Communications, Inc., a Texas corporation and a wholly owned subsidiary of the Company (“CareView
Texas”) and certain subsidiary guarantors party thereto, as grantors, in favor of PDL, as collateral agent, and its
permitted successors and assignees, as amended, modified, supplemented or restated from time to time.

 

(q)           “PDL
Credit Agreement” means that certain Credit Agreement, dated on or about June 26, 2015, by and among the Company, CareView
Texas, as the borrower, PDL, as the lender, and PDL, not individually, but as the agent, as amended, modified, supplemented or
restated from time to time.

 

    	- 4
                                                                                                                                                                             -

    	 

    

 

  (r)            “PDL
Subordination Agreement” means that certain Subordination and Intercreditor Agreement, dated on or about June 26, 2015,
by and among PDL, as agent for the first lien claimholders described therein, and each of the Investors, as initial second lien
claimholders therein, as amended, modified, supplemented or restated from time to time.

 

3.              Section
7.1 (Definitions) is hereby amended by deleting in its entirety the defined term “Revolving Debt Facility”.

 

4.              No
Further Amendments. Except as amended by this Amendment, the Purchase Agreement shall remain in full force and effect in accordance
with its terms.

 

5.              Miscellaneous.

 

a.              Ratification
and Confirmation. The Company acknowledges, agrees and confirms that: (x) the Purchase Agreement and each of the other Transaction
Documents, as amended and otherwise modified by the amendments and other modifications specifically provided herein or contemplated
hereby, are and shall continue to be in full force and effect and are hereby in all respects ratified and confirmed; and (y) without
limiting the generality of the foregoing clause (x), all obligations, liabilities and Indebtedness of the Company under the Transaction
Documents, as amended hereby, constitute “Obligations” (as defined in the Security Agreement) secured by and entitled
to the benefits of the security set forth in the Security Agreement and the IP Security Agreement, and the liens and security
interests granted in favor of the Investors under the terms of the Security Agreement and the IP Security Agreement are and remain
perfected, effective, enforceable and valid and such liens and security interests are hereby in all respects ratified and confirmed,
it being understood that such liens and security interests granted in favor of the Investors are subject to the PDL Subordination
Agreement to the extent described therein.

 

b.              Expenses.
The Company will pay and bear full responsibility for the reasonable legal fees and other out-of-pocket costs and expenses of
the Investors attributable to the negotiation and consummation of the transactions contemplated hereby.

 

c.             
Further Assurances. The Company shall duly execute and deliver, or cause to be duly executed and delivered, at its own
cost and expense, such further instruments and documents and to take all such action, in each case as may be necessary or proper
in the reasonable judgment of the Investors to carry out the provisions and purposes of this Amendment.

 

d.              Survival.
The representations, warranties, covenants and agreements made herein shall survive any investigation made by any party hereto,
the execution and delivery of this Amendment and the closing of the transactions contemplated hereby.

 

e.              Governing
Law. All questions concerning the construction, interpretation and validity of this Amendment shall be governed by and construed
and enforced in accordance with the domestic laws of the State of Delaware without giving effect to any choice or conflict of
law provision or rule (whether in the State of Delaware or any other jurisdiction) that would cause the application of the laws
of any jurisdiction other than the State of Delaware. In furtherance of the foregoing, the internal law of the State of Delaware
will control the interpretation and construction of this Amendment, even if under such jurisdiction’s choice of law or conflict
of law analysis, the substantive law of some other jurisdiction would ordinarily or necessarily apply.

 

    	- 5
                                                                                                                                                                             -

    	 

    

 

f.              Construction.
The Company and the Investors acknowledge that the Company and its independent counsel and the Investors and their independent
counsel have jointly reviewed and drafted this document, and agree that any rule of construction and interpretation to the effect
that drafting ambiguities are to be resolved against the drafting party shall not be employed.

 

g.             Counterparts;
Facsimile and Electronic Signatures. This Amendment may be executed in any number of counterparts, and each such counterpart
hereof shall be deemed to be an original instrument, but all such counterparts together shall constitute but one agreement. Counterpart
signatures to this Amendment delivered by facsimile or other electronic transmission shall be acceptable and binding.

 

h.             Headings.
The section and paragraph headings contained in this Amendment are for reference purposes only and shall not affect in any way
the meaning or interpretation of this Amendment.

 

[Signature
Pages Follow]

 

    	- 6
                                                                                                                                                                             -

    	 

    

 

IN
WITNESS WHEREOF, each of the undersigned has duly executed this Seventh Amendment to Note and Warrant Purchase Agreement as
of the date first written above. 

	 	 	 	 
	 	COMPANY:	 
	 	 	 	 
	 	CareView Communications, Inc., A Nevada corporation
	 	 	 	 
	 	By:	    /s/
    Steven G. Johnson	 
	 	 	Name: Steven G. Johnson	 
	 	 	Title:   President	 

	 	 	 
	 	MAJORITY INVESTORS: 	 
	 	 	 
	 	HealthCor Partners Fund, L.P.	 
	 	By: HealthCor Partners Management L.P., as Manager	 
	 	By: HealthCor Partners Management, G.P., LLC, as General Partner	 

	 	 	 	 	 
	 	By:	    /s/
    Jeffrey C. Lightcap	 
	 	Name: Jeffrey C. Lightcap	 
	 	Title: Senior Managing Director	 
	 	 	 	 
	 	Address:	HealthCor Partners	 
	 	 	Carnegie Hall Towers	 
	 	 	152 West 57th Street	 
	 	 	New York, NY 10019	 

	 	 	 	 	 
	 	HealthCor Hybrid Offshore Master Fund, L.P.
	 	By: HealthCor Hybrid Offshore G.P., LLC, as General
    Partner
	 	 	 	 
	 	By:	    /s/
    Joseph P. Healey	 
	 	Name: Joseph P. Healey	 
	 	Title: Co-CEO	 
	 	 	 	 
	 	Address:	HealthCor Partners	 
	 	 	Carnegie Hall Towers	 
	 	 	152 West 57th Street	 
	 	 	New York, NY 10019	 

 

    	 

    	 

    

 

ACKNOWLEDGED
AND AGREED:

 

CareView
Communications, Inc., a Texas corporation 

	 	 	 	 
	By:	 	/s/
    Steven G. Johnson	 
	 	 	Name: Steven G. Johnson	 
	 	 	Title:   President	 

	 	 	 	 
	By:	 	/s/
    Steven G. Johnson	 
	 	 	Name: Steven G. Johnson	 
	 	 	Title:   PresidentC

 

Careview Communication, Inc. 8-K

Exhibit 10.09

 

AMENDMENT TO 

REGISTRATION RIGHTS AGREEMENT

 

This AMENDMENT TO REGISTRATION
RIGHTS AGREEMENT, dated as of June 26, 2015 (this “Amendment”), is made by and among CAREVIEW COMMUNICATIONS,
INC., a Nevada corporation (the “Company”), and the undersigned investors (together with their respective
successors and permitted assigns, the “Investors”).

 

WITNESSETH:

 

WHEREAS, the Company,
HealthCor Partners Fund, L.P. (“HealthCor Partners”), HealthCor Hybrid Offshore Master Fund, L.P. (“HealthCor
Hybrid” and, together with HealthCor Partners, the “HealthCor Parties”), and certain additional investors
are party to that certain Registration Rights Agreement, dated as of April 21, 2011 (as amended from time to time, the “Registration
Rights Agreement”); and

 

WHEREAS, the Company
and PDL BioPharma, Inc., a Delaware corporation, are entering into on the date hereof that certain Registration Rights Agreement,
dated as of the date hereof (as amended from time to time, the “PDL Registration Rights Agreement”); and

 

WHEREAS, pursuant
to Section 11(c) of the Registration Rights Agreement and subject to the terms and conditions contained herein, the Investors constitute
the Holders of not less than a majority of the then outstanding Registrable Securities and the Investors and the Company desire
to amend the Registration Rights Agreement as set forth herein for the purposes of, among other things, ensuring that the underwriter
cut back provisions in the Registration Rights Agreement are consistent with the underwriter cut back provisions in the PDL Registration
Rights Agreement.

 

NOW, THEREFORE, in
consideration of the mutual promises, representations, warranties and covenants contained herein and in the Registration Rights
Agreement, which represent integral components of the transactions contemplated hereby and thereby and shall be fully enforceable
by the parties hereto, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged,
the Company and the Investors mutually agree as follows:

 

1.           Definitions.  Capitalized
terms used in this Amendment but not defined in this Amendment shall have the meanings ascribed to them in the Registration Rights
Agreement.

 

    	 

    	 

    

 

2.           Amendments
to Registration Rights Agreement.

 

a.           Section
4(b) of the Registration Rights Agreement is hereby amended and restated in its entirety to read as follows:

 

(b)  In
the event of an Underwriting Request, the Company, together with all Holders proposing to distribute their securities through such
underwriting (the “Participating Stockholders”), shall enter into an underwriting agreement in customary form with
the managing underwriter(s) selected for such underwriting by the Requesting Stockholders, which underwriter(s) shall be reasonably
acceptable to the Company; provided, however, that no Holder shall be required to make any representations or warranties concerning
the Company or its business, properties, prospects, financial condition or related matters.  Notwithstanding any other
provision of this Section 4, if the managing underwriter(s) advises the Company and the Participating Stockholders in writing that
because the number of shares requested by the Participating Stockholders to be included in the registration exceeds the number
which can be sold in an orderly manner in such offering within a price range acceptable to the Requesting Stockholders or that
marketing factors require a limitation of the number of shares to be underwritten on behalf of the Participating Stockholders (the
“Underwritten Registration Cutback”), and such Underwritten Registration Cutback results in less than all of the Registrable
Securities of the Participating Stockholders that are requested to be included in such registration to actually be included in
such registration, then the Company will include in such registration, to the extent of the number which the Company is so advised
can be sold in (or during the time of) such offering without such interference or affect on the price or sale: (i) if the PDL Holders
have not exercised their right to request inclusion in such registration statement pursuant to the PDL Registration Rights Agreement,
such number of Registrable Securities shared pro rata among all of the Participating Stockholders based on the total number of
Registrable Securities held by each such Participating Stockholder, or (ii) if the PDL Holders have exercised their right to request
inclusion in such registration statement pursuant to the PDL Registration Rights Agreement, the aggregate of such number of (x)
Registrable Securities and (y) PDL Registrable Securities proposed to be included in such registration by the PDL Holders shared
pro rata among all of the Participating Stockholders and such PDL Holders based on the number of Registrable Securities and PDL
Registrable Securities being requested for inclusion, respectively, by each such Participating Holder and PDL Holder.  For
the avoidance of doubt, the Company shall not sell shares in any underwritten offering in connection with a Registration Statement
filed pursuant to Section 2 in the event of an Underwritten Registration Cutback.  “PDL Holders” shall mean
those holders of the Company’s securities party to that certain registration rights agreement dated June 26, 2015 by and
between the Company and PDL BioPharma, Inc., a Delaware corporation, as amended, supplemented or modified from time to time (the
“PDL Registration Rights Agreement”).  “PDL Registrable Securities” shall have the same meaning
as “Registrable Securities” as defined in the PDL Registration Rights Agreement.

 

    	- 2
                                                                                                                                                                                               -

    	 

    

 

b.           Section
8 of the Registration Rights Agreement is hereby amended and restated in its entirety to read as follows:

 

8.  Piggy-Back
Registrations.  If at any time during the Effectiveness Period, the Company shall determine to prepare and file with
the SEC a registration statement relating to an offering for its own account or the account of others under the Securities Act
of any of its equity securities, other than on Form S-4 or Form S-8 (each as promulgated under the Securities Act) or their then
equivalents relating to equity securities to be issued solely in connection with any acquisition of any entity or business or equity
securities issuable in connection with stock option or other employee benefit plans, then the Company shall send to the each Holder
written notice of such determination and if, within fifteen (15) days after receipt of such notice, any such Holder shall so request
in writing, the Company shall include in such registration statement all or any part of such Registrable Securities such Holder
requests to be registered.  Notwithstanding the foregoing, if the Company’s proposed registration of equity securities
hereunder is, in whole or in part, an underwritten public offering, and the managing underwriter of such proposed registration
determines and advises in writing that the inclusion of all Registrable Securities proposed to be included in the underwritten
public offering, together with any other issued and outstanding shares of the Company’s common stock proposed to be included
therein (such other shares hereinafter collectively referred to as the “Other Shares”), would interfere with the successful
marketing of the Company’s securities, then the total number of such securities proposed to be included in such underwritten
public offering shall be reduced, (i) first by the shares requested to be included in such registration by the holders of Other
Shares (excluding the shares requested for inclusion by the PDL Holders), and (ii) second, if necessary, (A) one-half (1⁄2)
by the securities proposed to be issued by the Company, and (B) one-half (1⁄2) by the aggregate of (x) the Registrable Securities
proposed to be included in such registration by the Holders and (y) the PDL Registrable Securities proposed to be included in such
registration by the PDL Holders, on a pro rata basis, based upon the number of Registrable Securities and PDL Registrable Securities
being requested for inclusion, respectively by each such Holder and PDL Holder. The shares of the Company’s common stock
held by the Holders that are excluded from the underwritten public offering pursuant to the preceding sentence shall be withheld
from the market by the holders thereof for a period, not to exceed 90 days from the closing of such underwritten public offering
plus such additional period of time as may be required to comply with Rule 2711 of the Financial Industry Regulatory Authority,
Inc. or any similar or successor rules thereto, that the managing underwriter reasonably determines as necessary in order to effect
such underwritten public offering.  Notwithstanding anything to the contrary contained herein, the amount of Registrable
Securities required to be included in the initial Registration Statement as described in this Section 8 shall not exceed the lesser
of (a) the amount of Registrable Securities that Holders request to have so registered pursuant to this Section 8 and (b) the maximum
amount of Registrable Securities which may be included in a Registration Statement without exceeding the Rule 415 Amount.

 

3.           No
Further Amendments.  Except as amended by this Amendment, the Registration Rights Agreement shall remain in full
force and effect in accordance with its terms.

 

    	- 3
                                                                                                                                                                                               -

    	 

    

 

4.           Miscellaneous.

 

a.           Governing
Law.  This Amendment shall be governed by, and construed and interpreted in accordance with, the laws of the State
of Delaware, without giving effect to principles of conflicts of law or choice of law that would cause the laws of any other jurisdiction
to apply.

 

b.           Construction.  The
Company and the Investors acknowledge that the Company and its independent counsel and the Investors and their independent counsel
have jointly reviewed and drafted this document, and agree that any rule of construction and interpretation to the effect that
drafting ambiguities are to be resolved against the drafting party shall not be employed.

 

c.           Counterparts;
Facsimile and Electronic Signatures.  This Amendment may be executed in any number of counterparts, and each such
counterpart hereof shall be deemed to be an original instrument, but all such counterparts together shall constitute but one agreement.  Counterpart
signatures to this Amendment delivered by facsimile or other electronic transmission shall be acceptable and binding.

 

d.           Headings.  The
section and paragraph headings contained in this Amendment are for reference purposes only and shall not affect in any way the
meaning or interpretation of this Amendment.

 

[Signature Pages Follow]

 

    	- 4
                                                                                                                                                                                               -

    	 

    

 

IN WITNESS WHEREOF,
the parties hereto have executed this Amendment to Registration Rights Agreement as of the date and year first set forth above.

 

	 	CAREVIEW COMMUNICATIONS, INC.
	 	 
	 	 By:	/s/ Steven Johnson
	 	 	Name: Steven G. Johnson
Title:   President

 

[SIGNATURE PAGE TO AMENDMENT
TO REGISTRATION RIGHTS AGREEMENT]

 

    	 

    	 

    

 

	 	INVESTORS:
	 	 
	 	HEALTHCOR PARTNERS
FUND, L.P.
	 	 
	 	By: HealthCor Partners
Management L.P., as Manager
	 	 
	 	By: HealthCor Partners Management, G.P., LLC, as General Partner
	 	 
	 	By:	/s/ J. C. Lightcap
	 	Name: Jeffrey C. Lightcap
Title: Senior Managing Director

 

	 	HEALTHCOR HYBRID
OFFSHORE MASTER FUND, L.P.
	 	 
	 	By: HealthCor Hybrid Offshore G.P., LLC, as General Partner
	 	 
	 	 By:	/s/ Joseph P. Healey
		Name: Joseph P. Healey
Title:   Co-CEO

 

[SIGNATURE PAGE TO AMENDMENT
TO REGISTRATION RIGHTS AGREEMENT]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00246-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00246-of-00352.parquet"}]]